Charles Schwab
VTGN icon

Charles Schwab’s VistaGen Therapeutics VTGN Stock Holding History

Charles Schwab’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-23,302
Closed -$15.4K – 3525
2025
Q4 		$15.4K Hold
23,302
– – ﹤0.01% 3452
2025
Q3 		$82.7K Hold
23,302
– – ﹤0.01% 3401
2025
Q2 		$46.6K Hold
23,302
– – ﹤0.01% 3454
2025
Q1 		$58.3K Hold
23,302
– – ﹤0.01% 3390
2024
Q4 		$68.7K Hold
23,302
– – ﹤0.01% 3423
2024
Q3 		$70.1K Hold
23,302
– – ﹤0.01% 3393
2024
Q2 		$81.1K Hold
23,302
– – ﹤0.01% 3481
2024
Q1 		$123K Hold
23,302
– – ﹤0.01% 3290
2023
Q4 		$120K Buy
+23,302
New +$88.2K ﹤0.01% 3333
2023
Q2 		– Sell
-16,484
Closed -$61.7K – 3687
2023
Q1 		$61.7K Buy
16,484
+2,219
+16% +$11.6K ﹤0.01% 3312
2022
Q4 		$44.1K Hold
14,265
– – ﹤0.01% 3383
2022
Q3 		$66K Sell
14,265
-3,760
-21% -$37.3K ﹤0.01% 3271
2022
Q2 		$476K Sell
18,025
-415
-2% -$14.7K ﹤0.01% 3097
2022
Q1 		$686K Buy
18,440
+2,259
+14% +$98.5K ﹤0.01% 2996
2021
Q4 		$947K Buy
16,181
+11
+0.1% +$716 ﹤0.01% 2935
2021
Q3 		$1.33M Buy
16,170
+358
+2% +$31.1K ﹤0.01% 2787
2021
Q2 		$1.5M Buy
15,812
+14,153
+853% +$1.05M ﹤0.01% 2805
2021
Q1 		$107K Buy
+1,659
New +$111K ﹤0.01% 3376

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Charles Schwab's VTGN Position: Q1 2026 in Review

Charles Schwab sold out of VistaGen Therapeutics (VTGN) in Q1 2026, closing a stake of 23,302 shares — an estimated $15.4K sold.

Charles Schwab first reported a position in VTGN in Q1 2021 and held it in 18 quarters. The position peaked at $1.5M in Q2 2021. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Charles Schwab reported no remaining VistaGen Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Charles Schwab sold 23,302 VistaGen Therapeutics shares in Q1 2026, an estimated $15.4K.
  • Charles Schwab first reported a position in VistaGen Therapeutics in Q1 2021 and held it in 18 quarters.
  • Charles Schwab's VistaGen Therapeutics position peaked at $1.5M in Q2 2021.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.